Fulgent Genetics faces a challenging outlook as its core testing business exhibits inconsistent revenue growth and severe margin compression, with gross margins falling 1,210 basis points from 42.2% in 2025Q3 to 30.1% in 2026Q2. The company's operational model...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | -$0.58-26.1% vs -$0.46 | $85M-9.2% vs $94M |
Q2 2026 May 1, 2026 | -$0.36-3.4% vs -$0.35 | $71M+4.5% vs $68M |
Q1 2026 Feb 27, 2026 | $0.16+433.3% vs $0.03 | $83M-2.4% vs $85M |
Q4 2025 Nov 7, 2025 | $0.14+158.3% vs -$0.24 | $84M-1.5% vs $85M |
Hsbc Holdings PLC purchased a new stake in shares of Fulgent Genetics, Inc. (NASDAQ: FLGT) in the second quarter, according to the company in its most recent filing with the SEC. The fund purchased 45,048 shares of the company's stock, valued at approximately $915,000. Hsbc Holdings PLC owned about 0.16% of Fulgent Genetics
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics NASDAQ: FLGT reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% from a year earlier, as the company incorporated a full quarter of contributions from Bako Diagnostics and StrataDx. Management also lowered its full-year revenue outlook, citing lower collection rates during a transition to a new billing and revenue-cycle-management system.
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to earnings of $0.07 per share a year ago.
Benchmark FLGT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Fulgent Genetics, Inc. (FLGT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $21.65 | $614.87M | -10.99 | 13.83% | -18.75% | -5.41% | — | |
| $390.90 | $55.98B | -257.17 | 35.9% | -7.11% | -11.73% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $1.47 | $456.58M | -0.81 | 3.89% | -82.49% | -4961.74% | — | |
| $311.54 | $25.55B | 29.78 | 7.25% | 6.99% | 11.55% | — | |
| $234.85 | $25.92B | 26.84 | 11.78% | 9.19% | 14.09% | — |
Fulgent Genetics, Inc. (FLGT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Fulgent Genetics, Inc. (FLGT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jun 2, 2026·SEC
May 21, 2026·SEC
Get notified when FLGT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Fulgent Genetics, Inc. (FLGT) stock FAQ — growth, dividends, profitability & financials explained
Fulgent Genetics, Inc. (FLGT) reported $323.9M in revenue for fiscal year 2025. This represents a 25247% increase from $1.3M in 2014.
Fulgent Genetics, Inc. (FLGT) grew revenue by 13.8% over the past year. This is steady growth.
Fulgent Genetics, Inc. (FLGT) reported a net loss of $84.4M for fiscal year 2025.
Fulgent Genetics, Inc. (FLGT) has a return on equity (ROE) of -5.4%. Negative ROE indicates the company is unprofitable.
Fulgent Genetics, Inc. (FLGT) had negative free cash flow of $103.8M in fiscal year 2025, likely due to heavy capital investments.
